Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

RGLS has been the subject of a number of other reports. Canaccord Genuity Group reissued a “hold” rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Leerink Partnrs downgraded Regulus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th. Jones Trading restated a “hold” rating and issued a $7.00 price target (down previously from $8.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Wells Fargo & Company restated an “equal weight” rating and issued a $9.00 price target on shares of Regulus Therapeutics in a report on Thursday, May 1st. Finally, Leerink Partners restated a “market perform” rating and issued a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.50.

Regulus Therapeutics Price Performance

RGLS opened at $7.95 on Friday. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $8.20. The stock has a market capitalization of $550.41 million, a price-to-earnings ratio of -7.43 and a beta of 0.49. The business has a fifty day moving average price of $3.54 and a 200 day moving average price of $2.15.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.14. On average, research analysts anticipate that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

Hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its holdings in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares in the last quarter. PEAK6 LLC acquired a new stake in shares of Regulus Therapeutics during the fourth quarter valued at about $95,000. Octagon Capital Advisors LP grew its stake in shares of Regulus Therapeutics by 13.7% during the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company’s stock valued at $7,661,000 after acquiring an additional 585,101 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Regulus Therapeutics by 20.5% during the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 19,900 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.